Travere Therapeutics (NasdaqGM:TVTX) announced a planned CEO and President transition effective December 1, 2026. Dr. Eric ...
Travere Therapeutics has delivered a very large share price gain over the past few years, which naturally puts the focus on ...
Finnmark er ikke som resten av landet. Stein-Tore Lund tror derfor at 2026 kan bli det beste året for bilbutikken han styrer.
Eric Dube, Ph.D., the CEO who rebranded Travere Therapeutics and oversaw the launch of its rare kidney disease drug Filspari, will ...
Travere Therapeutics teilte am Mittwoch mit, dass das Unternehmen vom US-Patent- und Markenamt eine Mitteilung über die ...
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...
Travere Therapeutics, Inc. und Eric Dube, Ph.D., haben am 21. September 2026 im gegenseitigen Einvernehmen den Zeitplan und ...
Detailed price information for Veeva Systems Inc (VEEV-N) from The Globe and Mail including charting and trades.
A Travere informou que seu medicamento renal FILSPARI continua ganhando tração tanto na nefropatia por IgA (IgAN) quanto na ...
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,120, titled ...
Investing.com - Guggenheim ha alzato il proprio obiettivo di prezzo su Travere Therapeutics ( NASDAQ:TVTX) a $89 da $75 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results